These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 22877506)

  • 1. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
    Wandt H; Schaefer-Eckart K; Wendelin K; Pilz B; Wilhelm M; Thalheimer M; Mahlknecht U; Ho A; Schaich M; Kramer M; Kaufmann M; Leimer L; Schwerdtfeger R; Conradi R; Dölken G; Klenner A; Hänel M; Herbst R; Junghanss C; Ehninger G;
    Lancet; 2012 Oct; 380(9850):1309-16. PubMed ID: 22877506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.
    Desborough M; Estcourt LJ; Doree C; Trivella M; Hopewell S; Stanworth SJ; Murphy MF
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010982. PubMed ID: 27548292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
    Estcourt LJ; Stanworth S; Doree C; Trivella M; Hopewell S; Blanco P; Murphy MF
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010984. PubMed ID: 26505729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
    Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
    Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
    Crighton GL; Estcourt LJ; Wood EM; Trivella M; Doree C; Stanworth S
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010981. PubMed ID: 26422767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
    Rebulla P; Finazzi G; Marangoni F; Avvisati G; Gugliotta L; Tognoni G; Barbui T; Mandelli F; Sirchia G
    N Engl J Med; 1997 Dec; 337(26):1870-5. PubMed ID: 9407153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
    Bornhäuser M; Kienast J; Trenschel R; Burchert A; Hegenbart U; Stadler M; Baurmann H; Schäfer-Eckart K; Holler E; Kröger N; Schmid C; Einsele H; Kiehl MG; Hiddemann W; Schwerdtfeger R; Buchholz S; Dreger P; Neubauer A; Berdel WE; Ehninger G; Beelen DW; Schetelig J; Stelljes M
    Lancet Oncol; 2012 Oct; 13(10):1035-44. PubMed ID: 22959335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A no-prophylaxis platelet-transfusion strategy for hematologic cancers.
    Stanworth SJ; Estcourt LJ; Powter G; Kahan BC; Dyer C; Choo L; Bakrania L; Llewelyn C; Littlewood T; Soutar R; Norfolk D; Copplestone A; Smith N; Kerr P; Jones G; Raj K; Westerman DA; Szer J; Jackson N; Bardy PG; Plews D; Lyons S; Bielby L; Wood EM; Murphy MF;
    N Engl J Med; 2013 May; 368(19):1771-80. PubMed ID: 23656642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial.
    Lye DC; Archuleta S; Syed-Omar SF; Low JG; Oh HM; Wei Y; Fisher D; Ponnampalavanar SSL; Wijaya L; Lee LK; Ooi EE; Kamarulzaman A; Lum LC; Tambyah PA; Leo YS
    Lancet; 2017 Apr; 389(10079):1611-1618. PubMed ID: 28283286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation.
    Wandt H; Schaefer-Eckart K; Frank M; Birkmann J; Wilhelm M
    Bone Marrow Transplant; 2006 Feb; 37(4):387-92. PubMed ID: 16400342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study.
    Tay J; Allan D; Beattie S; Bredeson C; Fergusson D; Maze D; Sabloff M; Thavorn K; Tinmouth A
    BMJ Open; 2016 Oct; 6(10):e013483. PubMed ID: 27798034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
    Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
    Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation.
    Stanworth SJ; Hyde C; Heddle N; Rebulla P; Brunskill S; Murphy MF
    Cochrane Database Syst Rev; 2004 Oct; (4):CD004269. PubMed ID: 15495093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An audit of platelet transfusion within the Wellington Cancer Centre.
    Buhrkuhl DC; Karlsson MK; Carter JM
    Intern Med J; 2012 Jan; 42(1):65-70. PubMed ID: 21040321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 x 10(9) and 20 x 10(9) per L.
    Nevo S; Fuller AK; Hartley E; Borinsky ME; Vogelsang GB
    Transfusion; 2007 May; 47(5):801-12. PubMed ID: 17465944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose of prophylactic platelet transfusions and prevention of hemorrhage.
    Slichter SJ; Kaufman RM; Assmann SF; McCullough J; Triulzi DJ; Strauss RG; Gernsheimer TB; Ness PM; Brecher ME; Josephson CD; Konkle BA; Woodson RD; Ortel TL; Hillyer CD; Skerrett DL; McCrae KR; Sloan SR; Uhl L; George JN; Aquino VM; Manno CS; McFarland JG; Hess JR; Leissinger C; Granger S
    N Engl J Med; 2010 Feb; 362(7):600-13. PubMed ID: 20164484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New strategies for the optimal use of platelet transfusions.
    Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
    Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
    Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.